Back to search

Article

Immune Response to GeneVac-B® (rDNA I.P. Hepatitis B Vaccine) in Vaccinated Persons with a Standard Schedule in Bobo-Dioulasso, Burkina Faso

2024-05-07

Abstract excerpt

GeneVac-B® was recently licensed in Burkina Faso and is widely used for population vaccination. This study aimed to evaluate the immune response in people fully vaccinated against hepatitis B with the GeneVac-B® vaccine in Burkina Faso under actual conditions of use. This cross-sectional study included individuals fully vaccinated with GeneVac-B®. For each consenting participant, sociodemographic and clinical data...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
64f19e7c-3524-5d3b-94a1-85f9a9d61de9
DOI
10.20944/preprints202405.0333.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Immune Response to GeneVac-B® (rDNA I.P. Hepatitis B Vaccine) in Vaccinated Persons with a Standard Schedule in Bobo-Dioulasso, Burkina FasoDOI 10.20944/preprints202405.0333.v1
Select a neighboring publication to make it the new centre.